[Sinovac Files 2014 Annual Report on Form 20-F The Company will provide a hard copy of its complete audited financial statements to its shareholders upon request, free of charge. Requests for a hard copy of the 2014 Annual Report can be made through the Contact IR page in the Investor Relations section of the Company's website by submitting complete mailing] []
[Sinovac Files 2014 Annual Report on Form 20-F The Company will provide a hard copy of its complete audited financial statements to its shareholders upon request, free of charge. Requests for a hard copy of the 2014 Annual Report can be made through the Contact IR page in the Investor Relations section of the Company's website by submitting complete mailing] []
[Sinovac Provides Updates on Pipeline Vaccines BEIJING, March 17, 2015 /PRNewswire/ -- Sinovac Biotech Ltd. ), a leading provider of biopharmaceutical products in China, today provided updates on the Company's pipeline vaccines. EV71 vaccine. EV71 is a virus that causes hand, foot and mouth disease (HFMD) and is the primary cause of most severe and fatal cases of hand, foot] [Sinovac to Participate in China Medical and Healthcare Investment Conference Beijing, March 18,2014/PRNewswire/--Sinovac Biotech Ltd.(NASDAQ:SVA), a leading provider of biopharmaceutical products in China, today announced that the Company will participate in the China Medical and Healthcare Investment Conference sponsored by T.H capital and Dong Xing Security, to be held at China World Hotel from March 23 to March 25. The] [Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2014 Unaudited Financial Results BEIJING, April 10, 2015 -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced that it will release its unaudited financial results for the fourth quarter and full year, ended December 31, 2014, before market opens on Monday,] []
[Sinovac Provides Updates on Pipeline Vaccines BEIJING, March 17, 2015 /PRNewswire/ -- Sinovac Biotech Ltd. ), a leading provider of biopharmaceutical products in China, today provided updates on the Company's pipeline vaccines. EV71 vaccine. EV71 is a virus that causes hand, foot and mouth disease (HFMD) and is the primary cause of most severe and fatal cases of hand, foot] [Sinovac to Participate in China Medical and Healthcare Investment Conference Beijing, March 18,2014/PRNewswire/--Sinovac Biotech Ltd.(NASDAQ:SVA), a leading provider of biopharmaceutical products in China, today announced that the Company will participate in the China Medical and Healthcare Investment Conference sponsored by T.H capital and Dong Xing Security, to be held at China World Hotel from March 23 to March 25. The] [Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2014 Unaudited Financial Results BEIJING, April 10, 2015 -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced that it will release its unaudited financial results for the fourth quarter and full year, ended December 31, 2014, before market opens on Monday,] []
[SCHEDULE 13G (Amendment No. )* Sinovac Biotech Ltd. (Name of Issuer) Common Stock (Title of Class of Securities) P8696W104 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) x Rule 13d-1(b) o Rule 13d-1(c) o Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this]
[SCHEDULE 13G (Amendment No. )* Sinovac Biotech Ltd. (Name of Issuer) Common Stock (Title of Class of Securities) P8696W104 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) x Rule 13d-1(b) o Rule 13d-1(c) o Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this]
[(Name of Issuer) Common Stock (Title of Class of Securities) P8696W104 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * CUSIP No. P8696W104 1. NAMES OF REPORTING PERSONS 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP 3. SEC USE ONLY]
[(Name of Issuer) Common Stock (Title of Class of Securities) P8696W104 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * CUSIP No. P8696W104 1. NAMES OF REPORTING PERSONS 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP 3. SEC USE ONLY]
[Sinovac to Participate in Upcoming Investor Conferences BEIJING, September 2, 2014 -- Sinovac Biotech Ltd. (NASDAQ:SVA), a leading provider of biopharmaceutical products in China, today announced that the Company’s management will participate in the following investor conferences in September: · Morgan Stanley Global Healthcare Conference, to be held at the Grand Hyatt New York on September 9 and 10, 2014.] [Sinovac Announces New Presentation Time for Aegis Healthcare & Technology Conference BEIJING, September 5, 2014 -- Sinovac Biotech Ltd. (NASDAQ:SVA), a leading provider of biopharmaceutical products in China, today announced a new presentation time for the Aegis Healthcare & Technology Conference, to be held at the Wynn Las Vegas on September 12, 2014. Management will present at 8:00 am PT.] [Sinovac to Participate in Jefferies 4th Annual Asia Summit BEIJING, Oct. 21, 2014 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that the Company's management will host investor meetings at the Jefferies 4th Annual Asia Summit, to be held at the Island Shangri-La Hotel in Hong Kong on October 29-30, 2014.] [Sinovac to Host Conference Call to Report Third Quarter 2014 Unaudited Financial Results BEIJING, November 5, 2014 -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced that it will release its unaudited financial results for the third quarter, ended September 30, 2014, after market close on Friday, November 14, 2014 ET. The Company] [Sinovac Reports Unaudited Third Quarter Financial Results - Conference call scheduled for Monday, November 17, 2014 at 8:00 a.m. ET - BEIJING, Nov. 14, 2014 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced its unaudited financial results for the third quarter and nine months ended September 30, 2014. Third Quarter 2014] []
[Sinovac to Participate in Upcoming Investor Conferences BEIJING, September 2, 2014 -- Sinovac Biotech Ltd. (NASDAQ:SVA), a leading provider of biopharmaceutical products in China, today announced that the Company’s management will participate in the following investor conferences in September: · Morgan Stanley Global Healthcare Conference, to be held at the Grand Hyatt New York on September 9 and 10, 2014.] [Sinovac Announces New Presentation Time for Aegis Healthcare & Technology Conference BEIJING, September 5, 2014 -- Sinovac Biotech Ltd. (NASDAQ:SVA), a leading provider of biopharmaceutical products in China, today announced a new presentation time for the Aegis Healthcare & Technology Conference, to be held at the Wynn Las Vegas on September 12, 2014. Management will present at 8:00 am PT.] [Sinovac to Participate in Jefferies 4th Annual Asia Summit BEIJING, Oct. 21, 2014 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that the Company's management will host investor meetings at the Jefferies 4th Annual Asia Summit, to be held at the Island Shangri-La Hotel in Hong Kong on October 29-30, 2014.] [Sinovac to Host Conference Call to Report Third Quarter 2014 Unaudited Financial Results BEIJING, November 5, 2014 -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced that it will release its unaudited financial results for the third quarter, ended September 30, 2014, after market close on Friday, November 14, 2014 ET. The Company] [Sinovac Reports Unaudited Third Quarter Financial Results - Conference call scheduled for Monday, November 17, 2014 at 8:00 a.m. ET - BEIJING, Nov. 14, 2014 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced its unaudited financial results for the third quarter and nine months ended September 30, 2014. Third Quarter 2014] []
